Lipitor vs Crestor: Titration Speed and Tolerability Compared

How Quickly Does Each Statin Lower LDL?

Rosuvastatin reaches steady-state plasma concentrations in approximately one week, compared to one to two weeks for atorvastatin. In the STELLAR trial (N=2,431), rosuvastatin 10 mg lowered LDL by 46% at week 6 versus 37% for atorvastatin 10 mg, a statistically significant difference that held across every dose pair tested 1. For patients who need to hit an LDL target quickly before a procedure or after a cardiac event, that speed difference is clinically relevant.

Dose-for-Dose LDL Reduction

The ACC/AHA 2018 Cholesterol Guideline classifies statins by intensity rather than by molecule 2. High-intensity therapy is defined as achieving an LDL reduction of at least 50%. Atorvastatin 40 to 80 mg and rosuvastatin 20 to 40 mg both qualify as high-intensity, but the absolute percentage reductions differ.

At their respective maximum approved doses:

• Atorvastatin 80 mg: approximately 55% LDL reduction 3
• Rosuvastatin 40 mg: approximately 63% LDL reduction 3

That 8-percentage-point gap can matter for patients with baseline LDL above 190 mg/dL or those with familial hypercholesterolemia who need the maximum achievable reduction from monotherapy.

Half-Life and Dosing Flexibility

Atorvastatin has a half-life of roughly 14 hours (active metabolites extend this to about 20 to 30 hours), meaning it can be taken at any time of day 4. Rosuvastatin's half-life is approximately 19 hours, also permitting flexible timing 5. Neither drug requires bedtime dosing, unlike older statins such as lovastatin and simvastatin that depend on nocturnal cholesterol synthesis peaks.

Titration Schedules in Practice

The standard clinical approach is to start both drugs at a moderate dose and reassess lipid panels at four to six weeks. The FDA labels for both agents support titration at four-week intervals 4 5. Because rosuvastatin reaches steady-state slightly faster, some clinicians obtain a fasting lipid panel at three to four weeks rather than six when using rosuvastatin to allow an earlier dose adjustment decision.

Cardiovascular Outcome Trial Evidence

Both drugs have landmark randomized controlled trials supporting their use, but they tested different populations, making direct comparisons imperfect.

ASCOT-LLA: Atorvastatin in Hypertensive Patients

ASCOT-LLA (N=10,305) randomized patients with hypertension and at least three additional cardiovascular risk factors to atorvastatin 10 mg or placebo. The trial was stopped early after a median 3.3-year follow-up because atorvastatin reduced the primary endpoint of non-fatal MI and fatal coronary heart disease by 36% (hazard ratio 0.64, 95% CI 0.50 to 0.83, P<0.001) 6. Total cardiovascular events and procedures fell by 21%, and fatal or non-fatal stroke dropped by 27% 6.

JUPITER: Rosuvastatin in Patients with Elevated hsCRP

JUPITER (N=17,802) enrolled adults with LDL below 130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP ≥ 2 mg/L). Rosuvastatin 20 mg reduced the composite of MI, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44% versus placebo (hazard ratio 0.56, 95% CI 0.46 to 0.69, P<0.00001) 7. The trial also demonstrated a 50% reduction in LDL from a median baseline of 108 mg/dL, reaching a median on-treatment LDL of 55 mg/dL 7.

What the Trials Do and Do Not Tell Us

These trials enrolled different patients. ASCOT-LLA focused on prevention in those with established hypertension; JUPITER focused on a low-LDL, high-inflammation phenotype. No randomized trial has directly compared atorvastatin to rosuvastatin on hard cardiovascular endpoints in the same population. The 2018 ACC/AHA guideline does not prefer one high-intensity statin over the other for primary or secondary prevention on the basis of outcomes alone 2.

Tolerability and Side Effects

Myopathy and CK Elevation

Statin-associated muscle symptoms (SAMS) affect an estimated 5 to 10% of statin users in real-world practice, though rates in controlled trials are much lower 8. True myopathy (CK elevation greater than 10 times the upper limit of normal) occurs in fewer than 1 in 10,000 patients for both drugs 9.

In the PRIMO study (N=7,924), which surveyed statin users in France for musculoskeletal symptoms, rosuvastatin showed a musculoskeletal symptom rate of 10.1% compared to 14.9% for atorvastatin at doses achieving equivalent LDL reductions 10. That finding has not been uniformly replicated, and both the European Atherosclerosis Society and the ACC/AHA note that individual susceptibility varies more than drug class 8.

Rhabdomyolysis risk for both drugs is very low at approved doses. The FDA removed cerivastatin from the market in 2001 due to rhabdomyolysis, but neither atorvastatin nor rosuvastatin carries that profile at standard doses 11.

Hepatotoxicity

Clinically significant liver enzyme elevation (greater than 3 times the upper limit of normal) occurs in fewer than 1% of patients taking either drug at approved doses 4 5. Routine liver function monitoring is no longer recommended by the ACC/AHA for asymptomatic statin users 2. Check a baseline panel before starting therapy; recheck only if symptoms suggest hepatic injury.

New-Onset Diabetes Risk

Both statins carry an FDA class warning for increased blood glucose and HbA1c 11. A 2010 meta-analysis (N=91,140 participants across 13 trials) found statin therapy was associated with a 9% increased risk of new-onset diabetes (odds ratio 1.09, 95% CI 1.02 to 1.17) 12. The JUPITER trial found rosuvastatin 20 mg increased new-onset physician-reported diabetes by 25% versus placebo over a median 1.9 years 7. Whether rosuvastatin carries a higher intrinsic diabetes risk than atorvastatin remains debated; a 2013 network meta-analysis found higher-intensity statins carry modestly greater risk regardless of molecule 13.

Cognitive Effects

The FDA added a class label update in 2012 noting reports of cognitive impairment (memory loss, forgetfulness, confusion) with all statins 11. Prospective studies have not confirmed a causal relationship. The PROSPER trial (N=5,804), which used pravastatin and enrolled adults aged 70 to 82, found no difference in cognitive decline versus placebo over 3.2 years 14.

Drug Interactions: A Key Differentiator

This is arguably where atorvastatin and rosuvastatin diverge most clinically.

CYP3A4 Metabolism

Atorvastatin is extensively metabolized by cytochrome P450 3A4. Co-administration with strong CYP3A4 inhibitors, including clarithromycin, itraconazole, HIV protease inhibitors, and some antifungals, can raise atorvastatin plasma concentrations by 3- to 10-fold 4. The FDA label caps atorvastatin at 20 mg when used with clarithromycin or itraconazole 4. Elevated plasma levels of any statin directly increase myopathy risk.

Rosuvastatin's Interaction Profile

Rosuvastatin is metabolized minimally by CYP2C9 and is primarily eliminated unchanged. It does not interact with CYP3A4 inhibitors in a clinically meaningful way 5. However, rosuvastatin's plasma concentrations rise approximately 2-fold with concomitant cyclosporine use, and the FDA label contraindicates the combination 5. Antacids containing aluminum and magnesium hydroxide can reduce rosuvastatin AUC by about 54%; dosing should be separated by at least two hours 5.

Clinical Takeaway on Interactions

For patients on HIV antiretroviral regimens, certain antifungals, or macrolide antibiotics for chronic conditions, rosuvastatin is typically the safer choice from an interaction standpoint. For patients taking cyclosporine (as in transplant medicine), atorvastatin is generally preferred 4 5.

Renal and Hepatic Dosing Adjustments

Renal Impairment

Rosuvastatin requires a starting dose of 5 mg and a maximum dose of 10 mg in patients with severe renal impairment (creatinine clearance <30 mL/min not on hemodialysis), because plasma concentrations increase approximately 3-fold in this population 5. Atorvastatin does not require dose adjustment in renal impairment because it is primarily hepatically eliminated 4. For CKD patients who need high-intensity statin therapy, this makes atorvastatin a simpler choice.

Hepatic Impairment

Both drugs are contraindicated in active liver disease or unexplained persistent elevations in serum transaminases 4 5. For patients with compensated cirrhosis or mild chronic liver disease, neither drug has a definitive edge; clinical judgment and close monitoring apply in both cases.

Switching From Atorvastatin to Rosuvastatin: When and How

Reasons to Switch

Clinicians most often consider switching from atorvastatin to rosuvastatin for one of four reasons:

1. The patient is on a CYP3A4 inhibitor that raises atorvastatin exposure significantly.
2. The patient has not reached their LDL target on atorvastatin 40 mg and tolerability limits dose escalation to 80 mg.
3. The patient reports muscle symptoms on atorvastatin and an alternative high-intensity statin is warranted before abandoning statin therapy entirely.
4. A preference for the slightly greater LDL-lowering potency at equivalent intensity classifications.

Dose Conversion

No direct regulatory guidance exists on a single conversion table. Based on the STELLAR trial data and the ACC/AHA intensity classifications 2 3, the commonly used clinical equivalences are:

• Atorvastatin 10 mg approximately equals rosuvastatin 5 to 10 mg
• Atorvastatin 20 mg approximately equals rosuvastatin 10 mg
• Atorvastatin 40 mg approximately equals rosuvastatin 20 mg
• Atorvastatin 80 mg approximately equals rosuvastatin 40 mg

A lipid panel should be obtained four to six weeks after any switch to confirm the expected LDL reduction has been achieved 2.

Switching for Muscle Symptoms

The ACC/AHA advises stopping the offending statin and rechallenging at a lower dose or switching to a different statin before concluding a patient is truly statin-intolerant 15. In the GAUSS-3 trial (N=511), 43% of patients previously labeled statin-intolerant tolerated atorvastatin 20 mg in a blinded crossover phase 16. That finding suggests true statin intolerance is less common than self-reported, and a switch to rosuvastatin at a conservative dose is a reasonable step before escalating to non-statin agents such as ezetimibe or a PCSK9 inhibitor.

The HealthRX clinical team uses the following stepwise approach when a patient reports SAMS on atorvastatin: (1) hold atorvastatin for four weeks and document symptom resolution; (2) rechallenge at the same dose to confirm causality; (3) if symptoms recur, switch to rosuvastatin at a dose one intensity level below the atorvastatin dose; (4) obtain CK and lipid panel at four weeks; (5) if rosuvastatin is also not tolerated, proceed to every-other-day rosuvastatin 5 to 10 mg or add ezetimibe to a lower statin dose before considering PCSK9 inhibitor therapy.

Race, Ethnicity, and Pharmacogenomics

East Asian Populations and Rosuvastatin

The FDA label for rosuvastatin recommends a starting dose of 5 mg in Asian patients, based on pharmacokinetic studies showing approximately 2-fold higher plasma exposure compared to Caucasian subjects 5. Atorvastatin does not carry a race-based dose recommendation. This difference does not mean rosuvastatin is contraindicated in Asian patients, it means the starting dose should be conservative and titration should proceed carefully.

SLCO1B1 Polymorphisms

Variants in the SLCO1B1 gene, which encodes the hepatic uptake transporter OATP1B1, reduce statin uptake into the liver and raise plasma statin concentrations. The Clinical Pharmacogenomics Implementation Consortium (CPIC) has published guidelines noting that SLCO1B1 poor-function alleles increase simvastatin-related myopathy risk substantially; data for atorvastatin and rosuvastatin suggest a similar but smaller magnitude of risk increase 17. Patients with known SLCO1B1 poor-function genotype may tolerate rosuvastatin better than simvastatin but should still be started at a conservative dose and monitored.

Cost and Access

Both drugs are available as generics at most U.S. Pharmacies for under $20 per month at standard doses. The brand-name Crestor remains available but offers no clinical benefit over generic rosuvastatin. GoodRx pricing as of mid-2025 shows generic atorvastatin 40 mg at approximately $9 to 12 per month and generic rosuvastatin 20 mg at approximately $14 to 18 per month at major chains. Neither drug requires prior authorization for most commercial insurance plans when prescribed for dyslipidemia meeting guideline criteria 2.

Current Guideline Recommendations

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol states: "High-intensity statin therapy should be initiated or continued as first-line therapy in patients who are most likely to benefit" 2. The guideline does not distinguish between atorvastatin and rosuvastatin as the preferred high-intensity agent; both are listed as high-intensity options.

The National Lipid Association similarly recognizes both drugs as appropriate for patients requiring LDL reductions of 50% or more 18. For secondary prevention patients with very high risk (LDL target <55 mg/dL per the 2019 ESC/EAS guidelines), the higher maximum LDL-lowering potency of rosuvastatin 40 mg may give it a practical edge when atorvastatin 80 mg cannot reach target 19.

The 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias specify: "For very high-risk patients, an LDL-C reduction of ≥50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) is recommended" 19. Achieving that goal from a baseline LDL of 160 mg/dL requires a 66% reduction, achievable with rosuvastatin 40 mg but at the edge of what atorvastatin 80 mg consistently delivers.

Practical Prescribing Summary

Atorvastatin is the right starting point for most patients because of its 30-year safety record, no renal dose adjustment requirement, extensive cardiovascular outcomes data from ASCOT-LLA and others, and the lowest generic cost. Start at 40 mg for high-intensity therapy; titrate to 80 mg if the four-week LDL check shows the patient has not reached target and tolerability is acceptable 4.

Rosuvastatin becomes the better option when: the patient is on a CYP3A4 inhibitor, they need the maximum achievable LDL reduction from a single agent (particularly for LDL targets <55 mg/dL), they are reporting atorvastatin-related muscle symptoms that warrant a trial of an alternative statin, or they are not on cyclosporine 5.

In Asian patients starting either drug, begin rosuvastatin at 5 mg and atorvastatin at 10 to 20 mg and titrate based on the four-week lipid panel rather than assuming dose equivalences derived from predominantly White trial populations 5 17.

Recheck a fasting lipid panel and CK (if muscle symptoms exist) four to six weeks after any dose change or switch. If LDL remains above target on rosuvastatin 40 mg, add ezetimibe 10 mg before escalating to a PCSK9 inhibitor, as the combination can reduce LDL by an additional 18 to 25% 20.